Skip to main content
. 2014 Dec 17;5:5809. doi: 10.1038/ncomms6809

Figure 8. A β-catenin antagonist suppresses Men1-deficient tumour cell proliferation and improves hypoglycemia in mice.

Figure 8

(a) Body weight of βMen1-KO mice treated with PKF115-584 (0.5 mg kg−1) or vehicle (n=7–8). The untreated and treated groups represent the beginning and end of treatment. (b,c) Fasting blood glucose and fasting serum insulin levels in βMen1-KO mice treated with PKF115-584 or vehicle (n=6–8). The data represent the mean±s.d., *P<0.05, **P<0.01, Student’s t-test. (d) Western blot analyses of active and total β-catenin, Mcm2 and cyclin proteins in PNETs from βMen1-KO mice treated with PKF115-584 or vehicle. The data shown represent three independent experiments. (e,f) Analysis of Ki67 staining in PNETs from βMen1-KO mice treated with PKF115-584 or vehicle (n=3 for each group). Scale bars, 100 μm.